{
    "Trade/Device Name(s)": [
        "Access SHBG",
        "Access Sex Hormone Binding Globulin Reagent"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K233480",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083867"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "February 8, 2024",
    "Summary Letter Received Date": "December 14, 2023",
    "Submission Date": "January 30, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Sex Hormone Binding Globulin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Immunoenzymatic ('sandwich') assay",
        "Paramagnetic particle assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access SHBG chemiluminescent immunoassay for quantitative determination of Sex Hormone Binding Globulin on DxI 9000 Access Immunoassay Analyzer",
    "Indications for Use Summary": "Indicated for quantitative determination of Sex Hormone Binding Globulin in human serum and plasma for assessment of androgen disorders",
    "fda_folder": "Clinical Chemistry"
}